Talk:Cold-fX

message: Due to the lack of conclusive scientific evidence that the CVT-E002 extracted from the ginseng root has any major effect upon boosting the immune system to lessen cold and flu effects, one must think that CV technologies is exploiting people looking for a 'quick cure' for colds.  It seems to work mostly on the grounds that it is a placebo and people believe that it is making them feel better. (Bennyj600 (talk) 01:16, 16 April 2009 (UTC)
thread_title: Comment

message: I deleted the following section:  reads like an ad, no sources for individual facts. 
::Athlete Usage
"Through the years, the popularity of COLD-fX has grown, helped in a major way by athlete endorsements.  Over 300 elite Canadian athletes use COLD-fX regularly and 27 professional hockey teams and several football teams have also used the product.  Company spokespeople include:  Olympic Gold Medalist Clara Hughes, Hockey Legend Mark Messier, and Canadian hockey commentator Don Cherry, who were all approached by the company after they made it known that they were using COLD-fX. Other celebrities who have identified themselves as COLD-fX users include internationally renowned author Margaret Atwood, gifted theatrical vocalist Michael Burgess, Canadian Idol winner Eva Avila, actor Colin Mochrie and TV star and comedian Rick Mercer."
--Coppertwig (talk) 22:03, 24 November 2007 (UTC)
thread_title:  Deletion of athlete section 

message: "COLD-fX is a highly purified ChemBioPrint product derived from the roots of North American ginseng (Panax quinquefolius). Each capsule contains 200 mg of, CVT-E002™, a unique extract of polysaccharides that has been shown in laboratory and clinical studies to strengthen the immune system. Through CV Technologies’ proprietary process, COLD-fX undergoes vigorous testing to ensure that every batch has consistent chemical identity and biological activity." from  a website which is linked directly to from cvstechnologies -- the web site appears to be presented by the same company.  --Coppertwig (talk) 22:59, 24 November 2007 (UTC)
thread_title:  cvstechnologies 

message: I deleted the following.  Specific references are not given for the statements, and the wording reads too much like an ad:
:"Scientific studies have been published in nine peer-reviewed medical journals, including the Canadian Medical Association Journal. Some of the Cold-fX clinical trial findings include:<BR>
:* significantly enhanced the body’s first line of defense: the Natural Killer (NK) and Macrophage immune cells 
:* significantly enhanced production of cytokines which are critical to activate the body’s second line of defense, the T-lymphocytes 
:* reduced the relative risk of recurrent colds and the flu 
:* significantly reduced the severity and duration of cold and flu symptoms 
:* was safe and effective in strengthening the immune system 
:International Olympic Committee (IOC) protocol testing demonstrated that Cold-fX did not contain or induce any banned substances. "
--Coppertwig (talk) 23:22, 24 November 2007 (UTC)
thread_title:  Deletion of most of Clinical Evidence section 

message: I took off the prod template, and put a sources template instead.  I believe I've improved the article somewhat, and that it can be further improved.  Some statements do not have specific references given, but apparently there are many references for this topic so I think sources can be found.  You can help improve the article rather than deleting it.  --Coppertwig (talk) 23:26, 24 November 2007 (UTC)
thread_title:  Deleting prod template 

message: Manuscript in publication?  Wikipedia only uses published sources.  WhatamIdoing (talk) 03:43, 7 October 2008 (UTC)
thread_title: References

message: What's the notability criteria relevant to obscure brands? I can't imagine there's a criteria lax enough to allow articles on arbitrary brand name dietary supplements. Seppi333 (Insert 2¢) 07:30, 22 January 2014 (UTC)
replies: text: Might be worth merging to the active ingredient American ginseng. It is notable enough. Doc James (talk · contribs · email) (if I write on your page reply on mine) 07:36, 22 January 2014 (UTC)
replies: text:  Yeah, that seems like a reasonable solution.  I don't think it'd make much sense if this article were to be more detailed than the article on its active ingredient. Seppi333 (Insert 2¢) 07:43, 22 January 2014 (UTC)
replies: text: Will give some time for a few more to comment. Doc James (talk · contribs · email) (if I write on your page reply on mine) 07:48, 22 January 2014 (UTC)

text: Still American ginseng. I am happy with either a merge with a redirect or leaving it here. Doc James (talk · contribs · email) (if I write on your page reply on mine) 23:16, 22 January 2014 (UTC)
thread_title:  Notability 

message: What gives a secondary source its credibility that cannot be refuted? 
Just to note, both the Seida and Nahas secondary reviews are not peer-reviewed journal articles, where as many of the primary sources are (such as CMAJ).  This is a case where secondary review/research is poorly conducted, with 2 reviewers per article. That means the COLD-FX wikipedia content can only be based on the review conducted by 4 people. Does that seem credible to anyone? Yet secondary articles are the absolute gold standard (regardless of its quality) based on wikipedia policies.
Since primary sources cannot be cited, regardless of how many or how it was done, and that secondary sources appears to be weak, this COLD-FX page has no credibility in its content.  — Preceding unsigned comment added by 66.46.223.130 (talk) 22:47, 22 January 2014 (UTC)
replies: text: The Nahas article, at the bottom actually says 'This article has been peer reviewed' .  Dbrodbeck (talk) 22:57, 22 January 2014 (UTC)

text: The Seida article comes from a journal with an editorial board, it seems unlikely that they would publish non peer reviewed stuff.  As for your query about secondary reviews, go read WP:MEDRS.  Dbrodbeck (talk) 23:00, 22 January 2014 (UTC)
replies: text: First of all you state Nahas paper in Canadian Family Physician is "not peer-reviewed journal articles". This is obviously incorrect as it is peer reviewed.  Doc James (talk · contribs · email) (if I write on your page reply on mine) 23:11, 22 January 2014 (UTC)
thread_title: Secondary Sources

message: Valeant Pharmaceuticals the company that makes this product appear to be editing this article per here  Doc James (talk · contribs · email) (if I write on your page reply on mine) 23:25, 22 January 2014 (UTC)
thread_title: Company editing this article

message: So the review in CFP says "Treatment: There are no trials evaluating ginseng for treatment of the common cold."  which we summarized as "There is no evidence that Cold-fX is effective in those infected with the common cold."
The User:174.112.42.106 however changed it to "There is some evidence to support Cold-fX is effective in treating those infected with the common cold."  which of course is definitely not what the source says. Doc James (talk · contribs · email) (if I write on your page reply on mine) 23:32, 22 January 2014 (UTC)
thread_title: Changes by IPs

message: Hello fellow Wikipedians,
I have just modified  on Cold-fX. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
*Added archive https://web.archive.org/web/20120207163510/http://www.macleans.ca/homepage/magazine/article.jsp?content=20070326_103302_103302 to http://www.macleans.ca/homepage/magazine/article.jsp?content=20070326_103302_103302
When you have finished reviewing my changes, please set the checked parameter below to true or failed to let others know (documentation at ).
Cheers.—InternetArchiveBot (Report bug) 14:54, 27 November 2016 (UTC)
thread_title:  External links modified 

message: Hello fellow Wikipedians,
I have just modified one external link on Cold-fX. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
*Added archive https://web.archive.org/web/20131023061913/http://webprod3.hc-sc.gc.ca/lnhpd-bdpsnh/info.do?lang=eng&licence=80002849 to http://webprod3.hc-sc.gc.ca/lnhpd-bdpsnh/info.do?lang=eng&licence=80002849
When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
Cheers.—InternetArchiveBot (Report bug) 09:13, 10 August 2017 (UTC)
thread_title:  External links modified 

message: COLD-FX is a product derived from the roots of North American ginseng (Panax quinquefolius). It was formulated by Jacqueline Shan and originally manufactured by her company, Afexa Life Sciences Inc. (formerly called CV Technologies Inc.).Ramage, Norma (30 March 2009). “CV Technologies Rebrands as Afexa.”Marketing Magazine.   It was headquartered in Edmonton, Alberta, Canada and subsequently, the company and lead product was acquired by Valeant Pharmaceuticals International (headquartered in Laval, Quebec, Canada) in 2011.
The active ingredient in COLD-FX® Daily Support is a patented extract from North American ginseng (Panax quinquefolius).  There is mixed reviews about the efficacy of COLD-FX®Nahas, R; Balla, A (Jan 2011). "Complementary and alternative medicine for prevention and treatment of the common cold". Canadian Family Physician. 57 (1): 31–6. PMC 3024156. PMID 21322286.Seida, JK; Durec, T; Kuhle, S (2011). "North American (Panax quinquefolius) and Asian Ginseng (Panax ginseng) Preparations for Prevention of the Common Cold in Healthy Adults: A Systematic Review". Evidence-based complementary and alternative medicine : eCAM. 2011: 282151. doi:10.1093/ecam/nep068. PMC 3136130. PMID 19592479..  The efficacy of this extract has been tested in clinical trials conducted in collaboration with researchers from Canadian universities.  COLD-FX® has been assessed in 6 published randomized, double-blinded and placebo controlled clinical trials and 20+ published articlesPredy GN, Goel V, Lovlin RE et al . Immune modulating effects of daily supplementation of COLD-FX (a proprietary extract of North American ginseng) in healthy adults. J Clin Biochem Nutr 2006;39:162-7McElhaney J., et al. COLD-FX® Stimulates Cell Mediated Immune Response of Peripheral Leukocytes ex-vivo to Influenza Virus in National Hockey League Players. The Open Nutraceuticals Journal, 2010; 3: 25-29Vohra S, Johnston BC, Laycock KL et al. Safety and tolerability of North American ginseng extract in the treatment of pediatric upper respiratory tract infection: a phase II randomized, controlled trial of 2 dosing schedules. Pediatrics 2008; 122:e402-10.Predy GN, Goel V, Lovlin R, Donner A, Stitt L, Basu TK. Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-sacchardies for preventing upper respiratory tract infections: a randomized controlled trial. CMAJ. 2005;173:1043-1048.McElhaney JE, Goel V, Toane B, Hooten J, Shan JJ. Efficacy of COLD-fX in the prevention of respiratory symptoms in community-dwelling adults: a randomized, double-blinded, placebo controlled trial. J Altern Complement Med. 2006;12:153-7.McElhaney JE, Simor AE, McNeil S, Predy GN. Efficacy and safety of CVT-E002, a proprietary extract of panax quiquefolius in the prevention of respiratory infections in influenza-vaccinated community-dwelling adults: a multicenter, randomized, double-blind and placebo-controlled trial. Influenza Res Treat. 2011; 2011: 1-8..  In vitro and clinical studies showed that COLD-FX® helps to reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system.Product Information.  COLD-FX®  is licensed by Health Canada as a Natural Health Product.Health Canada Natural Health Product Database. 
A review by Dr. Barrett and Dr. Brown from University of Wisconsin, which was published in American Botantical Council (A North America’s leading nonprofit research and education organization on herbal medicine) concluded that the clinical research on COLD-FX®  is “impressive” and promising, and these studies showed “evidence suggesting ability to prevent acute respiratory infections.”Barrett and Brown. Therapeutic Monograph for CVT-E002 (COLD-fX®). American Botanical Council. http://abc.herbalgram.org/site/DocServer/ColdFX_TheraMONO.pdf?docID=842American Botanical Council. New Release. http://www.prnewswire.com/news-releases/herb-experts-report-on-benefits-of-canadian-remedy-for-cold-and-flu-symptoms-52117457.html According to Health Canada's Natural Health Product Directorate records, COLD-FX® claims to "help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system". However, there are conflicting opinions regarding the efficacy of COLD-FX® in the prevention of the common cold.  Others, took a more skeptical view on the efficacy of this herbal remedy, a common issue faced by most natural supplements. 
*Medical uses
COLD-FX® has a portfolio of natural health products that provides (proactive) Daily Support (Daily Support, Extra Strength and Chewables) and Symptom Relief of cold and flu symptoms (COLD-FX® First Signs®). The original COLD-FX® products were formulated with the active ingredient extracted from North American ginseng, which has shown to have immune modulating effect. The patented extract used in COLD-FX® is one of the few natural supplements which has gone through rigorous clinical studies.Herb Experts Report on Benefits of Canadian Remedy for Cold and Flu Symptoms. http://cms.herbalgram.org/press/5594COLDfX.html?ts=1494530921&signature=4be128249e0375a245acb7a034d4afb4  Blumenthal from American Botanical Council suggested that COLD-FX® “represents a new class of herb-based therapeutic products” and is a “result of intensive scientific research on a natural herb”. Clinical studies involving more than 1600 patients, showed that the active ingredient in COLD-FX® can help reduce and prevent common cold and flu symptoms when taken daily. ,Goel DP, Geiger JD, Shan JJ, Kriellaars D, Pierce GN. Doping-control urinalysis of a ginseng extract, Cold-FX®, in athletes. Int J Sport Nutr Exerc Metab. 2004;14:473-480. High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG. A randomized, controlled trial of panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol. 2012;10:195-201.McElhaney JE, Gravenstein S, Cole SK, Davidson E, O'neill D, Petitjean S, Rumble B, Shan JJ. A placebo-controlled trial of a proprietary extract of North American ginseng (CVT-E002) to prevent acute respiratory illness in institutionalized older adults. J Am Geriatr Soc. 2004;52:13-19.
*Adverse effects
Individuals requiring anti-coagulant therapy such as warfarin should avoid use of American ginseng. Not recommended for individuals with impaired liver or renal function. It is not recommended in those who are pregnant or breastfeeding. Other adverse effects include: headaches, anxiety, trouble sleeping and an upset stomach. 
*Criticism
The efficacy of COLD-FX® has been covered in the media.  In 2015 a class action lawsuit was launched that claimed that the manufacturer misled people."Cold-FX users were misled about top-selling cold and flu remedy, lawsuit alleges". National Post. March 31, 2015. Retrieved 23 June 2015.https://www.thestar.com/business/2016/11/16/cold-fx-class-action-lawsuit-tossed.html The lawsuit was subsequently dismissed in a B.C. Supreme Court ruling in 2017.“Cold-FX class action lawsuit tossed – Toronto Star”.  Thestar.com The appeal on this case was dismissed in 2018.B.C. Appeal Court rejects class action lawsuit aimed at Cold-FX". financialpost.com May 2 2018. All studies posing 'significant' results on its efficacy were funded by the manufacturer. Other criticisms point out that these studies have been small scale, with conspicuously shallow participant pools and lopsided gender distributions.Fighting the common cold. ABC news. http://abcnews.go.com/GMA/Flu/story?id=1247773 Researchers have pointed out that there aren't enough studies on the effects of any form of Ginseng on the common cold to form any conclusions.William Lin (2007-02-16). "Does ginseng really work? It depends on who you ask". The Ottawa Citizen. Scientists have argued that COLD-FX® has not been tested for its ability to treat a cold after an individual has been infected.Ginseng Unproven in U.S." Los Angeles Times. 2008-02-18. In addition, no studies have yet been performed to assess the possible long term side effects of taking the pills every day during the cold and flu season.  Afexa Life Sciences Inc. (formerly called CV Technologies Inc.), the makers of COLD-FX®, were criticized for making health claims about the product that have never been tested or verified scientifically. Up until February 2007, the company advised a regimen of 18 pills over a course of 3 days in order to obtain "immediate relief" from a cold. Health Canada's review of the scientific literature confirmed that this is not a claim that CV Technologies Inc. is entitled to make.Charlie Gillis (2007-03-26). "COLD-fX catches the sniffles again". Macleans Magazine. Archived from the original on 2012-02-07. The company formulated a separate product for this usage. A CV Technologies press release explained the change in the dosing regimen as a choice to take a two-tier approach application to Health Canada."COLD-fX     Sets Record Straight: Health Canada's Approval of New Medical Claims     Unchanged" (PDF). CV Technologies. March 5, 2007. 
*External links
*
TekConnect (talk) 00:21, 4 October 2018 (UTC)
thread_title: Some proposed changes

message: This diff shows the major differences between the article as it exists now and the proposed changes on this talk page. Those changes include:
# Deletion of secondary source discussing the purported inefficacy of the product while simultaneously adding primary source documents discussing the product's purported efficacy.  Per WP:MEDRS, references to secondary sources are suggested to use. 
# Numerous errors in formatting and WP:MOS adherence (e.g., the addition of ® at several points in the article, non-standard capitalization, etc.) are also preventing this text from being found acceptable. 
Regards,  Spintendo  08:15, 4 October 2018 (UTC)
thread_title: Reply 04-OCT-2018

message: COLD-FX is a product derived from the roots of North American ginseng (Panax quinquefolius). It was formulated by Jacqueline Shan and originally manufactured by her company, Afexa Life Sciences Inc. (formerly called CV Technologies Inc.).Ramage, Norma (30 March 2009). “CV Technologies Rebrands as Afexa.”Marketing Magazine.   It was headquartered in Edmonton, Alberta, Canada and subsequently, the company and lead product was acquired by Valeant Pharmaceuticals International (headquartered in Laval, Quebec, Canada) in 2011.
The active ingredient in COLD-FX® Daily Support is a patented extract from North American ginseng (Panax quinquefolius).  There is mixed reviews about the efficacy of COLD-FXNahas, R; Balla, A (Jan 2011). "Complementary and alternative medicine for prevention and treatment of the common cold". Canadian Family Physician. 57 (1): 31–6. PMC 3024156. PMID 21322286.Seida, JK; Durec, T; Kuhle, S (2011). "North American (Panax quinquefolius) and Asian Ginseng (Panax ginseng) Preparations for Prevention of the Common Cold in Healthy Adults: A Systematic Review". Evidence-based complementary and alternative medicine : eCAM. 2011: 282151. doi:10.1093/ecam/nep068. PMC 3136130. PMID 19592479..  The efficacy of this extract has been tested in clinical trials conducted in collaboration with researchers from Canadian universities.  COLD-FX has been assessed in 6 published randomized, double-blinded and placebo controlled clinical trials and 20+ published articlesPredy GN, Goel V, Lovlin RE et al . Immune modulating effects of daily supplementation of COLD-FX (a proprietary extract of North American ginseng) in healthy adults. J Clin Biochem Nutr 2006;39:162-7McElhaney J., et al. COLD-FX® Stimulates Cell Mediated Immune Response of Peripheral Leukocytes ex-vivo to Influenza Virus in National Hockey League Players. The Open Nutraceuticals Journal, 2010; 3: 25-29Vohra S, Johnston BC, Laycock KL et al. Safety and tolerability of North American ginseng extract in the treatment of pediatric upper respiratory tract infection: a phase II randomized, controlled trial of 2 dosing schedules. Pediatrics 2008; 122:e402-10.Predy GN, Goel V, Lovlin R, Donner A, Stitt L, Basu TK. Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-sacchardies for preventing upper respiratory tract infections: a randomized controlled trial. CMAJ. 2005;173:1043-1048.McElhaney JE, Goel V, Toane B, Hooten J, Shan JJ. Efficacy of COLD-fX in the prevention of respiratory symptoms in community-dwelling adults: a randomized, double-blinded, placebo controlled trial. J Altern Complement Med. 2006;12:153-7.McElhaney JE, Simor AE, McNeil S, Predy GN. Efficacy and safety of CVT-E002, a proprietary extract of panax quiquefolius in the prevention of respiratory infections in influenza-vaccinated community-dwelling adults: a multicenter, randomized, double-blind and placebo-controlled trial. Influenza Res Treat. 2011; 2011: 1-8..  In vitro and clinical studies showed that COLD-FX helps to reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system.Product Information. Archived from the original on 2013-10-23.  COLD-FX  is licensed by Health Canada as a Natural Health Product.Health Canada Natural Health Product Database. 
A review by Dr. Barrett and Dr. Brown from University of Wisconsin, which was published in American Botantical Council (A North America’s leading nonprofit research and education organization on herbal medicine) concluded that the clinical research on COLD-FX  is “impressive” and promising, and these studies showed “evidence suggesting ability to prevent acute respiratory infections.”Barrett and Brown. Therapeutic Monograph for CVT-E002 (COLD-FX). American Botanical Council. American Botanical Council. New Release.  According to Health Canada's Natural Health Product Directorate records, COLD-FX claims to "help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system". However, there are conflicting opinions regarding the efficacy of COLD-FX in the prevention of the common cold.  Others, took a more skeptical view on the efficacy of this herbal remedy. A common issue faced by most natural supplements such as  : That there is no evidence that it is effective in those infected with the common cold,  and the effect of preventative use is not clear.
*Medical uses
COLD-FX has a portfolio of natural health products that provides (proactive) Daily Support (Daily Support, Extra Strength and Chewables) and Symptom Relief of cold and flu symptoms (COLD-FX First Signs). The original COLD-FX products were formulated with the active ingredient extracted from North American ginseng, which has shown to have immune modulating effect. The patented extract used in COLD-FX is one of the few natural supplements which has gone through rigorous clinical studies.Herb Experts Report on Benefits of Canadian Remedy for Cold and Flu Symptoms.   Blumenthal from American Botanical Council suggested that COLD-FX “represents a new class of herb-based therapeutic products” and is a “result of intensive scientific research on a natural herb”. Clinical studies involving more than 1600 patients, showed that the active ingredient in COLD-FX can help reduce and prevent common cold and flu symptoms when taken daily. ,Goel DP, Geiger JD, Shan JJ, Kriellaars D, Pierce GN. Doping-control urinalysis of a ginseng extract, Cold-FX®, in athletes. Int J Sport Nutr Exerc Metab. 2004;14:473-480. High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG. A randomized, controlled trial of panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol. 2012;10:195-201.McElhaney JE, Gravenstein S, Cole SK, Davidson E, O'neill D, Petitjean S, Rumble B, Shan JJ. A placebo-controlled trial of a proprietary extract of North American ginseng (CVT-E002) to prevent acute respiratory illness in institutionalized older adults. J Am Geriatr Soc. 2004;52:13-19.
*Adverse effects
Individuals requiring anti-coagulant therapy such as warfarin should avoid use of American ginseng. Not recommended for individuals with impaired liver or renal function. It is not recommended in those who are pregnant or breastfeeding. Other adverse effects include: headaches, anxiety, trouble sleeping and an upset stomach. 
*Criticism
The efficacy of COLD-FX has been covered in the media.  In 2015 a class action lawsuit was launched that claimed that the manufacturer misled people."Cold-FX users were misled about top-selling cold and flu remedy, lawsuit alleges". National Post. March 31, 2015. Retrieved 23 June 2015. The lawsuit was subsequently dismissed in a B.C. Supreme Court ruling in 2017.“Cold-FX class action lawsuit tossed – Toronto Star”.  Thestar.com The appeal on this case was dismissed in 2018.B.C. Appeal Court rejects class action lawsuit aimed at Cold-FX". financialpost.com May 2 2018. All studies posing 'significant' results on its efficacy were funded by the manufacturer. Other criticisms point out that these studies have been small scale, with conspicuously shallow participant pools and lopsided gender distributions.Fighting the common cold. ABC news.  2005-10-25 Researchers have pointed out that there aren't enough studies on the effects of any form of Ginseng on the common cold to form any conclusions.William Lin (2007-02-16). "Does ginseng really work? It depends on who you ask". The Ottawa Citizen. Scientists have argued that COLD-FX has not been tested for its ability to treat a cold after an individual has been infected.Ginseng Unproven in U.S." Los Angeles Times. 2008-02-18. In addition, no studies have yet been performed to assess the possible long term side effects of taking the pills every day during the cold and flu season.  Afexa Life Sciences Inc. (formerly called CV Technologies Inc.), the makers of COLD-FX, were criticized for making health claims about the product that have never been tested or verified scientifically. Up until February 2007, the company advised a regimen of 18 pills over a course of 3 days in order to obtain "immediate relief" from a cold. Health Canada's review of the scientific literature confirmed that this is not a claim that CV Technologies Inc. is entitled to make.Charlie Gillis (2007-03-26). "COLD-fX catches the sniffles again". Macleans Magazine. Archived from the original on 2012-02-07. The company formulated a separate product for this usage. A CV Technologies press release explained the change in the dosing regimen as a choice to take a two-tier approach application to Health Canada."COLD-FX  Sets Record Straight: Health Canada's Approval of New Medical Claims Unchanged" (PDF). CV Technologies. March 5, 2007. 
*External links
*
TekConnect (talk) 00:21, 4 October 2018 (UTC)
replies: text: Sorry, , but there is concern that we should not accept copy written by paid agents for inclusion in the encyclopaedia, as this may be seen as native or deceptive advertising, and thus be illegal in the United States, the jurisdiction that governs Wikipedia. The content you propose does not read as either neutral or encyclopaedic, and appears to omit some potentially significant facts (that at least some of the university studies were financed by the company, for example). If there is some important error or omission of fact in the article, please feel free to mention it here, with the sources that support it. Edit requests that are both clear and brief (a sentence or two) are most likely to be accepted. Justlettersandnumbers (talk) 10:55, 8 November 2018 (UTC)
thread_title:  Some proposed changes Revised